Annual General Meeting of Active Biotech AB
(Thomson Reuters ONE) -
The Annual General Meeting of Active Biotech was held on May 26, 2016.
In accordance with the Board of Directors' proposal, it was resolved that no
dividend would be paid.
The board members and the managing director were discharged from liability with
respect to their management of the company for 2015.
In accordance with the Election Committee's proposal, the Board members Mats
Arnhög, Magnhild Sandberg-Wollheim, Peter Sjöstrand and Peter Thelin were re-
elected. The Meeting also resolved to re-elect Mats Arnhög as Chairman of the
Board. KPMG AB was re-elected as auditor.
Furthermore, in accordance with the Election Committee's proposal, the Meeting
resolved that the Election Committee shall be composed of representatives for
the three largest owners, as per the end of September, 2016, as well as the
Chairman of the Board.
The Meeting approved the Board's proposal concerning guidelines for remuneration
to the President and other senior executives. The guidelines conform to the
principles applied to date.
In accordance with the Board's proposal, the Meeting resolved to authorize the
Board, for a period that does not extend past the date of the next Annual
General Meeting, to resolve on the issue of not more than seven million new
shares and/or convertibles with the corresponding dilution effect, with or
without pre-emptive rights for the company's shareholders.
Lund, May 27, 2016
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
For further information, please contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory properties, is
in pivotal Phase 3 development for the treatment of relapsing remitting multiple
sclerosis. Also, laquinimod is in Phase 2 development for the treatment of
primary progressive multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, SILC, ANYARA and
paquinimod projects. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. This information was provided to the media
for publication at 8:30 a.m. CET on May 27, 2016.
160527_Årsstämma_2016_Eng:
http://hugin.info/1002/R/2015738/747453.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
[HUG#2015738]
Unternehmensinformation / Kurzprofil:
Datum: 27.05.2016 - 08:30 Uhr
Sprache: Deutsch
News-ID 474062
Anzahl Zeichen: 3561
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 241 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Annual General Meeting of Active Biotech AB"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
